Epilepsy is one of the most common neurological disorders in childhood and its prevalence is 0.5-1%. About 30% of all childhood epilepsies are intractable to anti-epileptic medications. The most severe forms usually begin in infancy associated with global developmental delay or cognitive dysfunction, defined as epileptic encephalopathy. Epileptic encephalopathy caused by an inherited metabolic disorder is intractable to anti-epileptic medications, unless it is treated with a disease specific diet, vitamin, amino acid or cofactor supplementations.
and complex partial seizures. In one patient with one of the inherited metabolic disorders, there can be multiple seizure types in combination. The age of seizure onset is usually neonatal or early infantile period. According to age of seizure onset, the examples of the inherited metabolic disorders include: (1) neonatal period: e.g. pyridoxine-dependent epilepsy, pyridoxalphosphate dependent epilepsy, molybdenum cofactor deficiency, non-ketotic hyperglycinemia; (2) infantile period: e.g. glucose transporter 1 deficiency, mitochondrial disorders, neuronal ceroid lipofuscinosis, biotinidase deficiency, Menkes disease and congenital disorders of glycosylation and (3) early childhood: e.g. creatine deficiency disorders, lysosomal storage disorders. In various inherited metabolic disorders, disease specific therapy is successful to achieve good seizure control and improve long-term neurodevelopmental outcome.
Intractable epilepsy with global developmental delay or history of developmental regression warrants detailed metabolic investigations for the possibility of an underlying inherited metabolic disorder. Identification of a treatable underlying inherited metabolic disorder is crucial for the initiation of an effective treatment. For the inherited metabolic disorders with no specific treatment, confirmation of the diagnosis in the index case will enable prenatal diagnosis for the future pregnancies.
